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1. Introduction 
Ischemic heart disease is the world’s leading cause of mortality and also causes widespread 
morbidity and limitation of life-style. Coronary artery disease (CAD) is the predominant 
cause of ischemic heart disease and generally results from fixed coronary artery obstruction 
that limits myocardial oxygen delivery  relative to demand. Mortality associated with CAD 
is relatively high and was estimated at more than 1¼ million deaths in industrialized 
countries in 2001 (Lopez et al., 2006). Of note, CAD is projected to remain the primary basis 
of mortality at least through year 2030 (Mathers & Loncar, 2006). The impact of CAD on 
quality of life is even more impressive. The symptom that most commonly limits life-style in 
patients with CAD is angina pectoris. Angina pectoris is a symptom characterized by (1) 
substernal chest discomfort that is (2) predictably provoked by exertion or emotional stress, 
(3) lasts up to 20 minutes after the triggering activity is stopped, and (4) is relieved within 
minutes by nitroglycerin or rest. If all of these criteria are met, the symptom is called 
“typical angina pectoris”; if only 2 are met, the symptom is called “atypical angina”. If one 
or none are met, the symptom probably is non-cardiac in origin (Diamond et al., 1983). 
Typical angina has several different causes but predominantly results from CAD. Indeed, 
the presence of typical angina predicts CAD with a likelihood of 90%, while the association 
of atypical angina with CAD is reported to be 50%. CAD with ischemia also can cause other 
symptoms, such as abnormal chest sensations that do not meet the criteria for angina, 
dizziness, palpitation, dyspnea, etc. 
Angina pectoris is the presenting symptom in 50% of those with CAD (O'Rourke, 2010). 
Most often, this symptom is “stable”, i.e., after its onset, it occurs at a relatively predictable 
workload, frequency and severity. By convention, stable angina manifests little change in 
these characteristics over 2 weeks, though some variation can be expected if change occurs 
in myocardial oxygen demand, physical stress or ambient temperature (Braunwald et al., 
1994). In general, stable angina correlates with the stability or quiescence of an 
atherosclerotic plaque. Almost 20% of acute myocardial infarctions (MI) are preceded by 
chronic stable angina (Thom et al., 2006). This symptom must be distinguished from the less 
frequent “unstable angina”, considered to occur when angina first is manifest (“new onset 
angina”), or when angina-like discomfort is present at rest (i.e., without the activity/ 
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emotional stress trigger of typical angina), or when angina severity and frequency progress 
relatively rapidly. Most importantly, patients with unstable angina can be divided into low, 
intermediate or high short term risk of death or nonfatal MI (Gibbons et al., 1999). Patients 
at high and intermediate risk often have coronary artery plaques that have recently 
ruptured. Their risk of death is intermediate between that of patients with acute MI and 
patients with stable angina. Stable angina pectoris (hereafter denoted as “angina”) is 
common and disabling, affecting 30,000 to 40,000 per 1 million people in Europe and United 
States (Julian, 1997). As of 2006, approximately 10.2 million patients had angina in the 
United States. Angina often seriously limits routine daily activities and frequently leads to 
premature retirement from work (Julian, 1997). Despite availability and application of 
multiple anti-anginal drugs and mechanical therapy, angina remains very common in 
patients with known CAD, affecting 30 to 50% of such individuals (Gehi et al., 2008). One in 
3 patients with stable angina will have more than one episode per week. Epidemiologically, 
self reported angina substantially increases the risk of coronary events compared to its 
absence; this risk increases even more when angina is associated with exercise induced 
ischemia (Gehi et al., 2008). Regardless of the negative impact of angina on quality of life, in 
one study almost half of general practitioners considered angina in their patients to be 
optimally controlled in the face of persistent weekly symptoms (Beltrame et al., 2009).  
This chapter will review therapies currently available and in development for relief of acute 
episodes of angina and, more importantly, for prevention of this symptom in its chronic 
stable form (Table 1). Because, angina from CAD develops from myocardial oxygen supply-
demand imbalance, therapy for patients with CAD and angina is targeted to restore this 
balance. Indeed, the United States Food and Drug Administration will not approve a 
therapy for angina unless both the symptoms and the underlying ischemia are relieved in 
pre-approval testing because of concerns for patient safety if this symptomatic warning of 
ischemia is masked and the inciting activity continues. The major determinants of 
myocardial oxygen demand are heart rate (Fox et al., 2007; Heusch, 2008), systolic blood 
pressure and contractility. Indeed, experimentally, a twofold increase in any of these 
determinants of oxygen consumption requires approximately 50% increase in coronary 
blood flow if ischemia is to be avoided (Libby et al., 2008). The primary determinants of 
myocardial oxygen supply are coronary artery patency, perfusion pressure, arterial oxygen 
content and duration of diastole, when coronary flow occurs. Because of the high resting 
oxygen extraction by myocardial tissue, increase in myocardial oxygen consumption is 
primarily compensated by proportional increases in coronary flow and oxygen delivery.  
In patients with CAD, comprehensive management focuses not only on prevention and 
relief of the symptom but also on prevention of other sequelae common in patients with 
angina, including myocardial infarction, heart failure and death. Importantly, however, 
most antianginal therapies, pharmacological and mechanical, have not been assessed for 
their impact on adverse outcomes in patients with chronic stable angina. Management of 
patients with angina include life style modifications to prevent symptoms as well as to 
minimize known risk factors for adverse events, medications to prevent angina or to relieve 
acute episodes, medications to relieve risk factors (cholesterol-lowering agents, 
antihypertensive drugs, etc.), medications known to prevent other sequelae of CAD (e.g., 
anti-platelet drugs, certain angiotensin converting enzyme inhibitors) and revascularization 
or other mechanical therapy to relieve angina if it is inadequately managed with drugs 
alone. 
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Anti-Anginal Therapy Primary 
Pharmacological 
Effects 
Putative Anti-ischemic 
Mechanism 
Pharmacological Therapies
Nitrates Smooth muscle 
relaxation, 
vasodilatation 
(venodilation> 
arteriolardilation) 
↓↓preload, ↓afterload, (↓ 
myocardial oxygen 
demand), ↑oxygen supply 
Calcium Channel Blockers Smooth muscle 
relaxation (all), 
↓inotropy (some), 
↓chronotropy 
(some), ?improved 
endothelial function 
↓preload, ↓afterload, ↓ 
inotropy with ↓ 
contractility(some) 
(↓demand), ↑oxygen 
supply 
Beta adrenergic blockers ↓chronotropy, 
↓inotropy,  
↓blood pressure ↓demand, 
↑oxygen supply 
Miscellaneous    
a. Direct metabolic 
enhancers 
  
1. Ranolazine Inhibits fatty acid 
oxydation thus 
improving 
efficiency of 
oxydative 
metabolism, Na-
channel inhibition 
thus decreasing 
calcium overload 
Improved cellular 
metabolism 
2. Trimetazidine Inhibits palmitoyl-
carnitine oxidation, 
inhibit fatty acid 
oxydation 
Improved cellular 
metabolism 
b. Novel unloading or 
HR lowering drugs 
  
1. Ivabradine Inhibits If current, 
reduces HR, 
preserves LV 
inotropy and 
lusitropy, does not 
affect coronary 
vasomotion 
↓ myocardial oxygen 
demand, ↑oxygen supply 
2. Nicorandil Opens ATP 
sensitive K 
channels, 
vasodilator, 
↓preload, ↓afterload, 
(↓demand) 
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Anti-Anginal Therapy Primary 
Pharmacological 
Effects 
Putative Anti-ischemic 
Mechanism 
promotes 
endothelial NO 
synthase, reduces 
calcium toxicity 
3. Fasudil Rho-kinase 
inhibitor, coronary 
vasodilatation/anti-
spasmodic 
↑oxygen supply 
Mechanical Interventions Known effects  
a. Revascularization   
1. Coronary artery 
bypass grafting 
2. Coronary angio-
plasty/stenting 
Relieves mechanical 
obstructions to 
coronary arteries 
↑oxygen supply 
b. Enhanced external 
counterpulsation 
(EECP) 
Alters 
hemodynamics to 
improve coronary 
perfusion 
↑oxygen supply, ↓ 
myocardial oxygen 
demand 
c. Spinal cord 
stimulation 
Decreases pain and 
sympathetic tone 
↑oxygen supply,↓ 
myocardial oxygen 
demand 
d. Carotid sinus 
stimulation 
Increases 
parasympathetic 
tone 
↑oxygen supply,↓ 
myocardial oxygen 
demand 
Biological Therapy Putative Actions  
1. Transmyocardial laser 
revascularization 
direct perfusion of 
myocardium, 
angiogenesis, 
placebo or 
myocardial 
denervation 
↑oxygen supply 
2. Angiogenic gene therapy angiogenesis ↑oxygen supply 
HR=heart rate, K=potassium, LV=left ventricle, NO=nitric oxide 
Table 1. Antianginal anti-ischemic therapies, proven and putative 
Therapies shown to be effective in relieving acute episodes are limited to rapid onset, short 
acting nitrates and, though seldom used today, carotid sinus or spinal cord stimulation, all 
reviewed in this chapter. Prevention of angina can be achieved with a variety of drugs, 
though those most frequently employed today are beta blockers, calcium channel blockers 
and long acting nitrates. These and the other newer drugs now available will also be 
reviewed below. The various mechanical options, including coronary artery bypass grafting 
surgery, percutaneous coronary angioplasty, enhanced external counterpulsation, and laser-
mediated angiogenesis, will be summarized. Finally, the current status of approaches that 
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are not yet established but which hold promise for benefit and are under intensive study, 
including angiogenesis stimulated by growth factors directly or by gene insertions, and stem 
cell therapy, will be reviewed. Table 1 summarizes various approaches, pharmacological, 
mechanical and biological, now available or in relatively late stages of development. 
2. Pharmacological therapy 
2.1 Nitrates 
Nitrates have been the staple of treatment for acute episodes of angina pectoris for almost 
150 years, since the description of the effect of amyl nitrate for this condition in 1867 
(Brunton, 1867). Indeed, such use of amyl nitrate was included in the Lillian Hellman play, 
“The Little Foxes”, set just after the Civil War. Though the use of amyl nitrate has declined 
to application largely for diagnostic hemodynamic profiling for other conditions (e.g., 
idiopathic hypertrophic subaortic stenosis) other nitrates and, most particularly 
nitroglycerin, introduced by Murrell for this purpose in 1878 (Murrell, 1879), have gained 
enduring use, both for treatment of acute episodes and for prophylaxis.  
2.1.1 Pharmacological effects  
Like all anti-anginal anti-ischemic drugs, nitrates act to improve the imbalance of 
myocardial oxygen supply and demand that underlies angina (Grayson et al., 1967). Nitrates 
are believed to induce vasodilatation by interacting with sulfhydryl groups on nitrate 
receptors on cell membranes (Goldstein, 1979). The prototype nitrate, nitroglycerin, 
combines with sulfhydryls within smooth muscle cells, where the resulting molecule is 
biotransformed to an active form, S-nitrosothiol, by mitochondrial aldehyde dehydrogenase 
(Abrams, 1980). This short-lived compound activates intracellular guanylate cyclase to 
produce cyclic guanosine monophosphate. This molecule directly initiates smooth muscle 
relaxation to cause vasodilatation by decreasing myocytic intracellular calcium, either by 
inhibition of calcium ion entry or by promotion of calcium exit (Ignarro et al., 1981). This 
pharmacological effect renders nitroglycerin a potent vasodilator. Experimental studies 
suggest that nitroglycerin’s action as a venodilator may exceed that as an arterial and 
arteriolar dilator, though the drug acts on both sides of the circulation. It has been suggested 
that reduction in left ventricular (LV) preload, resulting from venous dilatation, is the 
primary basis for the drug-induced reduction in myocardial oxygen demand and, perhaps, 
the increase in myocardial oxygen supply observed with nitroglycerin and, thus, may be the 
primary basis for its anti-anginal anti-ischemic effect (Goldstein, 1979). However, reduction 
in LV outflow impedance due its arterial and arteriolar effects likely also is involved.  
Experimental evidence suggests that nitrates also may act directly to increase myocardial 
oxygen supply by dilatation of coronary arteries and arterioles. Conversion to nitric oxide, a 
deficiency of which is the putative basis of “endothelial dysfunction” observed in many 
patients with CAD (Parker & Parker, 1998), provides potential for vasodilatation and 
enhancement of coronary blood flow. However, the practical importance of this effect is 
unclear, since the calcified state of many atherosclerotic coronary arteries is likely to limit 
potential for arterial dilatation. Experimental evidence also suggests nitroglycerin may 
preferentially affect collateral vessels within the myocardium to increase flow to ischemic 
regions. Finally, as a result of preload reduction, nitroglycerin reduces LV diastolic pressure 
potentially enhancing perfusion pressure during diastole when most coronary flow occurs. 
This effect is apparent primarily in the subendocardium, where flow is particularly 
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vulnerable, though little change in total myocardial perfusion appears to be associated with 
this effect (Bottcher et al., 2002). Finally, in experimental studies, nitroglycerin has 
antithrombogenic action, apparently mediated via stimulation of guanylate cyclase in 
platelets (Munzel et al., 2002). This effect would tend to minimize platelet aggregation. The 
clinical importance of this change, particularly for angina, is not known.  
Irrespective of the underlying mechanisms, nitrates have been well demonstrated to 
increase exercise tolerance in patients with ischemic heart disease from CAD, while 
reducing ischemia as measured by increased time to ST segment depression during exercise 
in patients with chronic stable angina (Ben-Dor & Battler, 2007). Nitrates have additive effect 
when they are combined with beta-blockers or calcium channel blockers (Gibbons et al., 
2003).  
2.1.2 Clinical application 
Nitroglycerin preparations are available as sublingual tablets, buccal spray and ointment 
(both in immediately available and prolonged release [“patch”] forms), the latter for 
prophylaxis rather than for treatment of acute episodes. Nitroglycerin tablets lose potency 
when exposed to light and, hence, are stored in dark containers. The sublingual preparation 
is the treatment of choice for acute episodes of angina because this mode of administration 
enables absorption without first pass metabolism in the liver, resulting rapidly in 
therapeutic concentrations in the circulation. (Buccal spray has a similar advantage.) From 
drug levels in the plasma, the half-lives of the compounds differ markedly, nitroglycerin 
having a half-life of 2-3 min, isosorbide dinitrate (ISDN) 20-30 min and isosorbide 
mononitrate (ISMN) 4-5 h (Olsson & Allgen, 1992). The beneficial clinical effect of 
nitroglycerin has a half-life of 30 minutes; its hemodynamic effects are seen even after 2 
hours (Goldstein & Epstein, 1973). 
Metabolism to inactive forms occurs in the liver. The usual dose of nitroglycerin for relief of 
an acute angina episode is 0.4 mg by the sublingual route, though smaller (and larger) doses 
are effective in some patients. Nitroglycerin spray dispenses 0.4 mg metered, aerosolized 
doses, which are better absorbed in patients with dry mucous membranes. There is evidence 
to show that when used in sublingual form, nitroglycerin is an effective antianginal and 
anti-ischemic agent that can abort an attack of established angina and, when taken 
prophylactically, prolong exercise tolerance (Aronow, 1973; Detry & Bruce, 1971; Goldstein 
et al., 1971). If symptoms persist after a single dose, additional doses can be given, usually at 
5 minute intervals, though lack of relief with as much as 1.2 mg in a 15 minute interval 
suggests an acute coronary syndrome and should lead to emergency evaluation. Several 
long acting forms of nitrates have been developed. Their pharmacokinetics are such that 
they are not used for relief of acute angina episodes, but their persistence in the circulation 
and at active cellular sites can provide effective prophylaxis against angina. The most 
commonly employed are topical nitroglycerin ointment or nitroglycerin adherent to patches, 
oral ISDN and oral ISMN.  
Topical cutaneous administration of nitroglycerin is possible either with an ointment or a 
polymer patch impregnated with the drug. Nitroglycerin ointment usually is applied in 0.5 
– 2 inch doses, containing 15 mg of nitroglycerin per inch. The drug is effective for about 6 
hours by this route. Absorption can be impeded if skin perfusion is minimized by 
hypotension or impaired cardiac output. Nitroglycerin patches release the drug at a rate of 
0.1 to 0.8 mg/hour (depending on patch size) and are effective for approximately 12 to 18 
hours. Tolerance generally is absent if the patch is used for no more than 12 to 14 hours 
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daily. Oral ISDN has relatively low bioavailability, undergoing rapid hepatic metabolism. It 
is usually administered in a dose of 30 mg 3 to 4 times daily. The antianginal effect lasts for 6 
hours after the first dose, with decreased effect with each successive dose. Nitrate tolerance 
develops when it is administered four times daily. A dosing schedule permitting 
intermittent 10-12 hour nitrate free intervals helps to prevent tolerance.  
ISMN is the active metabolite of ISDN. When administered orally, it doesn’t undergo first 
pass metabolism and provides effective management of chronic stable angina. Steady state 
plasma concentration is achieved within 2 hours and its effect lasts for at least 8 hours. 
Tolerance is not reported when ISMN is administered once daily, but tolerance is common 
with twice daily dosing. A sustained release preparation is available in a dosage range from 
30 to 240 mg daily. Nitroglycerin can also be used as an intravenous preparation with 
titration to symptoms and blood pressure. Though not strictly relevant for relief of chronic 
stable angina, this form has been used for patients with frequent (“unstable”) angina at rest 
and requiring hospitalization (Frishman, 1985). It has also been used during acute coronary 
syndromes and has been effective in reducing ischemia during acute myocardial infarction 
(Borer et al., 1975) as well as in improving hemodynamics and reducing symptoms in heart 
failure, with or without infarction (Frishman, 1985).  
2.1.3 Adverse effects  
Most common adverse effects of nitrates and, specifically, of nitroglycerin, include 
headache, hypotension and flushing. These effects are due to vasodilatation. 
Methemoglobinemia is rare but reported after nitrate administration, most commonly after 
high doses of the intravenous form. Tolerance is reported with all forms of nitroglycerin. 
Tolerance to antianginal effects develops rapidly in humans during long-term, 4 times daily 
therapy with ISDN and continuous therapy with nitroglycerin patches (Crean et al., 1984; 
James et al., 1985; Parker & Fung, 1984; Reichek et al., 1984). The putative mechanism of 
tolerance is drug-induced generation of superoxide anions in the affected vessels, leading to 
impaired biotransformation and decreased responsiveness to nitric oxide (Gori & Parker, 
2004). Tolerance can be best avoided by providing a nitrate free period, optimally of 10 to12 
hours. Development of tolerance is rarely a problem when nitroglycerin sublingual tablets 
are taken intermittently, either for relief of an acute symptom or for short-term prophylaxis 
before activities predictably associated with angina. Some studies have shown that 
angiotensin receptor blockers may prevent nitrate tolerance (Hirai et al., 2003). Patients can 
develop rebound symptoms after abruptly stopping nitrates. With the recent increase in the 
use of sildenafil, a phosphodiesterase inhibitor, the dangers of interaction with nitrates have 
been highlighted, leading to proscription of this combination to prevent severe and 
potentially lethal hypotension.  
2.2 Calcium channel blockers 
Calcium Channel Blockers (CCB) bind to and inhibit L-type calcium channels, reducing 
calcium influx into cells. Intracellular calcium deprivation relaxes smooth muscle cells, 
causing vasodilatation in the peripheral and coronary beds and, in normal coronary arteries 
and perhaps diseased arteries, increased coronary blood flow. The 2 major subdivisions of 
CCBs are dihydropyridines (DHP) like nifedipine, amlodipine, felodipine, and nicardipine, 
and non-dihydropyridines which include verapamil and diltiazem. 
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2.2.1 Pharmacological effects  
CCBs’ main effect on angina is lowering myocardial oxygen demand by peripheral vascular 
smooth muscle relaxation. The result is to reduce blood pressure and impedance to LV 
outflow, in turn reducing myocardial wall tension, myocardial work load and oxygen 
consumption. However, they may cause dilatation of coronary arteries, as well, and thus 
may increase coronary blood flow/ myocardial perfusion. CCBs have been shown to be 
specifically and particularly effective in vasospastic angina pectoris (including “Prinzmetal’s 
angina”) and may be useful in effort-induced angina in part by relieving vasospasm 
associated with fixed obstructive lesions in some patients. In addition to vascular smooth 
muscle relaxation, the non-dihydropyridines also cause blockade of calcium entry into 
myocytes, leading to negative chronotropic effects due to action on the sinoatrial and 
atrioventricular nodal cells, and negative inotropic effects leading to depressed contractility 
due to action on ventricular myocytes. 
Experimentally, calcium plays an integral role in the process of atherogenesis. Hence, it has 
been theorized that CCBs are anti-atherogenic. Some studies have shown that CCBs reduce 
the progression of atherosclerosis as measured by carotid intima-media thickness but there 
has been no difference in coronary atherosclerosis. The ENCORE I trial demonstrated that 
nifedipine improved coronary endothelial function in the most constricted segment 
(Azancot, 2003) and the ENCORE II study showed that nifedipine improved coronary 
endothelial function but had no effect on plaque volume (Luscher et al., 2009). The NICOLE 
study showed no effect of CCBs on reduction of angiographic progression of CAD (Dens et 
al., 2003). Thus, clinical studies to date provide equivocal evidence of anti-atherogenesis but 
stronger support for improvement of endothelial function. 
2.2.2 Clinical application  
From multiple trials, CCBs decrease the frequency of angina, reduce the need for nitrates, 
extend treadmill walking time, and improve ischemic ST-segment changes on exercise 
testing and electrocardiographic monitoring (Gibbons et al., 2003; Heidenreich et al., 1999; 
Nissen et al., 2004; Rice et al., 1990). Amlodipine, in particular, may have some independent 
action in relieving diastolic dysfunction other than by a reduction in blood pressure (Tapp et 
al., 2010), potentially improving myocardial oxygen supply by enhancing perfusion 
pressure. CCBs are used in patients who cannot tolerate ǃ-blockers or in combination with 
other anti-ischemic agents for additive benefit. Though clearly effective antianginal agents, 
CCBs have not been found to modify the natural progression of CAD and have no effect on 
cardiovascular or all cause mortality in patients with CAD. DHP tend to cause reflex 
tachycardia because of lowering of blood pressure; this effect can be blunted by concomitant 
use of ǃ-blockers. If clinically needed, verapamil or diltiazem may be used with caution to 
lower heart rate or slow atrioventricular (AV) conduction further when ventricular function 
is preserved. In a case control study among enrollees of the Group Health Cooperative of 
Puget Sound, a link was reported between short-acting nifedipine and coronary events 
when the drug was used as primary therapy for hypertension (Psaty et al., 1995). However, 
short-acting nifedipine never has been approved by the FDA for use for this indication (i.e., 
its use was “off label”), and its application for this purpose by the Puget Sound group was 
an act of highly questionable judgment. Meta-analysis by Furberg et al showed that 
nifedipine is associated with dose related increase in mortality in patients with CAD, a 
study which included patients with acute coronary syndromes (ACS) (Furberg et al., 1995). 
However, the only trial included in the meta-analysis that involved patients with stable 
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angina was the International Nifedipine trial on Antiatherosclerotic Therapy (INTACT), 
which showed that patients on nifedipine had retardation of atherosclerotic disease by 
angiogram, though clinical symptoms were not reported (Lichtlen et al., 1990). A Coronary 
Disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system 
(ACTION) study reported that, in patients with stable angina and hypertension, long-acting 
nifedipine was acceptably safe (no increased incidence of myocardial infarction, heart 
failure or death), but there was no evidence of improvement in mortality or other major 
cardiac endpoints and no reduction in refractory angina in already maximally medically 
treated patients (Poole-Wilson et al., 2004; Sierra & Coca, 2008). In addition to 
vasodilatation, verapamil acts in part through its negative inotropic effect. Diltiazem has 
greater vasodilatory actions than verapamil. Both verapamil and diltiazem are 
contraindicated in patients with uncompensated heart failure because of their negative 
inotropic effects, whereas amlodipine and felodipine are relatively safe when LV 
dysfunction is present, particularly if compensated clinically (Sierra & Coca, 2008). Use of 
non-dihydropyridines after complex myocardial infarctions should be avoided, as well, 
because of the possibility of HF. 
Although CCBs are effective anti-ischemic agents, they do not improve mortality in patients 
with ACS. DHP can also cause reflex tachycardia which can be deleterious in acute ischemia 
by increasing myocardial oxygen demand. In addition, DHP-induced hypotension may 
detrimentally lower coronary perfusion pressure. A meta-analysis of trials of CCBs and long 
acting nitrates did not show any difference in clinical outcomes between these types of 
agents (Heidenreich et al., 1999). Nifedipine is a potent, long-acting vasodilator that has 
proved highly efficacious in relieving angina caused by coronary vasospasm. In vivo, it 
exerts no myocardial depressant effects and has no antiarrhythmic properties. Nifedipine is 
available in doses of 10-30 mg given 3 times daily and in sustained release preparations in 
doses of 60 to 120 mg that can be administered once daily. Onset of action is 20 minutes after 
administration and half life is 2-5 hours. Steady state concentrations are reached in 48 hours. 
Immediate release formulation is not recommended for hypertension because of concerns of 
sudden hemodynamic compromise but it is still approved for coronary spasm and 
management of angina. Treatment with nifedipine can safely be combined with 
administration of a ǃ receptor blocking agent.  
Verapamil is usually started with 40 mg three times daily and titrated to a maximum dose of 
480 mg daily. Sustained release preparations are available and can be given in doses of 120 
mg daily to 480 mg daily. Onset of action of verapamil is in 30 minutes; elimination half life 
is 3-7 hours. Diltiazem is available in doses of 30-90 mg given up to four times daily. A 
sustained release or long-acting form usually is administered at a starting dose of 120 mg 
daily and can be increased to 360 mg daily. Its onset of action is within 30-60 minutes and it 
has a half life of 3-7 hours. It can take up to 2 weeks to achieve maximal effect of diltiazem. 
2.2.3 Adverse effects  
Common side effects of headache, dizziness, flushing and edema (particularly with DHP) 
are due to vasodilatation. Verapamil and diltiazem can interact with other negative 
chronotropic or negative inotropic agents to produce substantial bradycardia, conduction 
disturbances or clinically overt heart failure. CCBs may also suppress lower esophageal 
sphincter contraction and worsen gastroesophageal reflux. Particularly with verapamil and, 
to a lesser extent with diltiazem, bowel motility can be importantly reduced, causing 
constipation, a particularly frequent complaint in relatively elderly patients given these 
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drugs. CCBs inhibit the CYPA4 enzyme in the liver and, therefore, may raise levels of statins 
and  other drugs, resulting in adverse effects of the drugs so affected (Furberg et al., 1978). 
By blocking the microsomal enzymes, the liver enzymes that metabolize CCBs, cimetidine 
and grapefruit juice may raise blood CCB concentrations. Since magnesium is a calcium 
antagonist, magnesium supplements may enhance the actions of CCBs, particularly 
nifedipine. 
2.3 Beta-blockers 
Adrenergic receptors are G-protein-coupled molecules stimulated by circulating 
catecholamines. These receptors are broadly classified into ǂ and ǃ groups. Effects of ǃ-
receptors are mediated by adenyl cyclase. ǃ-receptors are further classified into ǃ1 and ǃ2 
subtypes. ǃ1 stimulation results in increased chronotropy, inotropy, automaticity, release of 
renin from juxtaglomerular cells and lipolysis. ǃ2 effects include relaxation of bronchial, 
vascular and other smooth muscle, with dilatation of peripheral, coronary, and carotid 
arteries, and promotion of glycogenolysis and gluconeogenesis. ǃ-blockers are effective in 
preventing angina because they lower heart rate, reduce blood pressure, and reduce 
contractility, thereby reducing myocardial oxygen demand (Gibbons et al., 2003). However, 
of these effects, current data indicate that the most important is reduction in heart rate, the 
primary determinant of myocardial oxygen demand (Andrews et al., 1993; Borer et al., 2003; 
Daly et al., 2010). Most antianginal effects of ǃ-blockers result from ǃ1 inhibition. Also, 
because of the heart rate reduction, ǃ-blockers can enhance myocardial oxygen supply by 
prolonging diastole, when coronary perfusion occurs. However, by blocking ǃ2 receptors 
that can mediate coronary vasodilatation, some ǃ-blockers can allow unopposed ǂ-
adrenergic stimulation, leading to coronary vasoconstriction and mitigating the potentially 
beneficial effects of prolongation of diastole. ǃ-blockers also have negative lusitropic 
(relaxation) effects on the myocardium, minimizing the rate at which LV pressure falls 
during diastole and, thus, minimizing the increase in perfusion pressure that otherwise 
might be expected during prolonged diastole that drives coronary flow. 
2.3.1 Pharmacological effects  
Some ǃ-blockers are partial agonists, manifesting intrinsic sympathomimetic activity, 
blunting secondary preventive benefits (Freemantle et al., 1999). These generally are not 
used for angina prevention. Some newer ǃ-blockers, such as labetalol, carvedilol, and 
bucindolol, also have partial ǂ1-adrenergic blocking effects, causing vasodilatation. Others 
have antiarrhythmic effects – propranolol, metoprolol, and carvedilol have effects similar to 
“class I” (sodium-channel blockade) antiarrhythmics, while sotalol has a “class III” 
(potassium channel blockade) effect. Further, experimentally, carvedilol and its metabolites 
have antioxidant and antiproliferative properties that inhibit apoptosis. Most ǃ-blockers are 
well absorbed. ǃ-blockers that are lipid-soluble, such as propranolol and metoprolol, have 
short half-lives because they are metabolized by the liver. Hydrophilic ǃ-blockers such as 
atenolol and nadolol are eliminated through kidney and have longer half-lives.  
Atenolol is usually started with a dose of 50 mg daily and can be titrated to a suggested 
maximal dose of 200 mg daily. Metoprolol can be started with 50-100 mg daily and titrated 
for heart rate and blood pressure. When used to prevent angina, ǃ-blockers generally are 
titrated to a resting heart rate of 50–60 bpm and an exercise heart rate 75% of the rate that 
precipitates ischemia. In patients with severe angina, target heart rates of 50 bpm are 
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sometimes used if neither symptoms (fatigue, lightheadedness) nor atrioventricular block 
supervenes. 
2.3.2 Clinical application  
ǃ-blockers have been primary therapeutics for angina management  since early after their 
development (Hoekenga & Abrams, 1984); indeed, slowing heart rate to prevent angina was 
the primary reason for their development, for which a Nobel Prize was awarded. Many ǃ-
blockers have been studied in chronic stable angina (Furberg et al., 1978; Jackson et al., 
1978). ǃ-blockers have been shown to reduce mortality in patients with relatively recent MI, 
primary angioplasty for ST elevation MI and CHF with LV dysfunction. However, no 
randomized trials ever have been performed to assess the effects of ǃ-blockers on natural 
history outcomes in patients only with stable angina. Hence ǃ-blockers are titrated for 
maximal symptom benefit with least adverse effects. No differences have been shown in 
antianginal effects of different beta blockers when they are titrated to similar heart rate 
reductions. ǃ-blockers can be combined with nitrates, CCBs and other antianginals to 
enhance symptom relief. 
2.3.3 Adverse effects  
Absolute contraindications to ǃ-blockers are severe bradycardia with or without conduction 
system disease, severe asthma or peripheral vascular disease with rest ischemia, depression, 
and acute decompensated heart failure (HF). ǃ-blockers may cause dyslipidemia (increase in 
triglycerides and decrease in high-density lipoprotein cholesterol). The most common 
adverse effect is fatigue, a common complaint of patients receiving these agents. Mild 
depression, lack of motivation and erectile dysfunction have been well reported. ǃ-blockers 
may blunt the tachycardic response to hypoglycemia in diabetics; worsening of 
hypoglycemia in diabetics on oral agents or insulin has been reported. ǃ-blockers enhance 
insulin resistance, possibly accounting for the hyperglycemia. Patients with cocaine-induced 
coronary vasoconstriction may also react adversely when given ǃ-blockers, with 
hypertension and seizures. Similarly, since ǃ-adrenergic receptors may be up-regulated 
when patients are treated with ǃ-blockers, these agents should not be abruptly discontinued, 
lest rebound vasoconstriction precipitate unstable angina or even MI or death (Miller et al., 
1975; Psaty et al., 1990). Patients with asthma, claudication, or HF whose symptoms increase 
with ǃ-blockers should be appropriately monitored and reevaluated for possible 
substitution with CCBs. 
2.4 Ranolazine 
Ranolazine is a piperazine derivative that has been shown to prevent stable angina pectoris. 
This agent was approved by FDA in 2006 for use in combination with other antianginals 
when angina is not adequately controlled with established therapies. 
2.4.1 Pharmacological effects 
The pharmacological effects most likely to underlie ranolazine’s antianginal action are not 
fully elucidated. Several such effects have been suggested. Ranolazine has been shown to 
alter myocyte metabolism to favor oxidation of glucose over fatty acid by partial fatty acid 
oxidation (p-FOX) (Clarke et al., 1996). Less oxygen is required to metabolize glucose than 
fatty acids; consequently, ranolazine may improve efficiency of oxidative metabolism, 
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allowing more mechanical activity for a given oxygen supply. However, in formal clinical 
testing, though time to angina was increased with ranolazine versus placebo, no evidence 
was found that cardiac workload at angina was increased when angina occurred, thus 
casting doubt on improved metabolic efficiency as the underlying cause of the drug’s 
benefit. Experimentally, ranolazine reduces calcium overload in the ischemic myocyte 
through inhibition of the late sodium current (INa) (Antzelevitch et al., 2004; Belardinelli L, 
2004). Excess intracellular sodium activates the sodium-calcium exchanger and can result in 
intracellular calcium overload via reverse transport of the sodium calcium exchanger. 
Ranolazine appears to minimize the intracellular consequences of myocardial ischemia by 
reducing excess late sodium ion influx, thereby reducing calcium overload (Chaitman & 
Sano, 2007). Indeed, the drug is now labeled to indicate that sodium channel inhibition is the 
most likely basis of its activity. However, the drug also has modest alpha- and ǃ-blocking 
properties. Ranolazine is extensively metabolized by cytochrome P450 (mainly the 3A4 
enzyme) and excreted mainly in urine, predominantly as metabolites (Abdallah & Jerling, 
2005; Chu N, 2003). The elimination half life in healthy individuals is 5.3 to 8.9 hours which 
is significantly increased in severe renal impairment (Jerling & Abdallah, 2005).  
2.4.2 Clinical application  
Ranolazine has been investigated in Monotherapy Assessment of Ranolazine in Stable 
Angina (MARISA) trial, in which the drug was found to be well tolerated and effective in 
increasing exercise duration and time to ST segment depression in a dose dependent 
manner (Chaitman, 2002). In the Combination Assessment of Ranolazine in Stable Angina 
(CARISA) study, ranolazine was compared to placebo on a background of treatment with 
either atenolol 50 mg daily, amlodipine 5 mg daily, or diltiazem 180 mg daily. Ranolazine 
was effective in increasing exercise duration and mean time to onset of angina compared to 
placebo. There was also reduction in the frequency of angina as well as nitroglycerin use 
compared to placebo. In this trial, a higher dose of ranolazine (1000 mg twice daily) 
provided no extra benefit compared to the lower dose (750 mg twice daily) (Chaitman et al., 
2004). In the Efficacy of Ranolazine in Chronic Angina (ERICA) trial, ranolazine was 
compared to a placebo on a background of amlodipine 10 mg daily. Again, ranolazine 
resulted in lower frequency of angina and nitroglycerin consumption and similar frequency 
of adverse effects (Stone et al., 2006). In the Metabolic Efficiency with Ranolazine for Less 
Ischemia in Non-ST Elevation (MERLIN-TIMI-36) trial, 6560 patients with acute coronary 
syndromes were randomized within 48 hours of symptom onset, to intravenous ranolazine 
or a placebo, in addition to standard therapy. Ranolazine was administered as a bolus of 200 
mg over 1 hour and then continued as an infusion for 12 to 96 hours, followed by 1000 mg 
twice daily orally. After a median follow-up of 348 days, there was no difference in all-cause 
mortality, sudden cardiac death, or frequency of symptomatic arrhythmias between 
ranolazine and placebo. Though the trial failed to support ranolazine as a means of 
improving natural history in patients with CAD, it demonstrated the overall favorable 
safety profile of ranolazine, crucial for its FDA approval given prior concerns about drug-
induced syncope and ECG QT prolongation with possible “pro-arrhythmia”, while 
supporting its effectiveness in reducing angina (Morrow et al., 2007).  
2.4.3 Adverse effects  
Ranolazine is fairly well tolerated. Adverse effects (primarily dizziness, nausea, asthenia 
and constipation) appear to be dose related. Thus, in clinical trials, fewer than 8% of patients 
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discontinued ranolazine due to adverse effects; three quarters of these withdrawals occurred 
at the 1500 mg twice daily dose. Consequently, the approved starting dose is 500 mg twice 
daily, with possible up titration to 750 mg twice daily and 1000 mg twice daily if lower 
doses do not adequately prevent angina (Chaitman et al., 2004). An extended release (ER) 
oral preparation is also available. Ketoconazole and diltiazem can increase ranolazine 
plasma concentrations; ranolazine increases digoxin plasma concentration (Jerling & 
Abdallah, 2005; Chaitman et al., 2004). Ranolazine prolongs QTc interval in a dose related 
manner but, as noted above,  MERLIN-TIMI 36 failed to demonstrate excessive sudden 
death with the drug (Scirica et al., 2007),  nor were these suggested in earlier, shorter trials. 
2.5 Ivabradine 
The principle of heart rate slowing for prevention of angina is well established based on 
pathophysiological studies and clinical assessments of heart rate lowering drugs (Daly et al., 
2010). Indeed, heart rate is the major determinant of myocardial oxygen demand and its 
increase is a precipating factor for ischemia or angina (Andrews et al., 1993; Borer et al., 
2003; Daly et al., 2010; Fox et al., 2007; Heusch, 2008; Tardif et al., 2005). Heart rate also 
predicts outcome in epidemiologic studies of patients with CAD, as well as those with heart 
failure, hypertension, and, indeed, in unselected free living populations without apparent 
heart disease (Daly et al., 2010; Diaz et al., 2005; Fox et al., 2007; Fox et al., 2008; Fox et al., 
2008; Tardif et al., 2009). For example, the Coronary Artery Surgery Study (CASS) registry 
showed after a 14 year follow-up that cardiovascular and overall mortality was directly 
related to heart rate at entry into the study (Diaz et al., 2005). Similar results were seen in the 
placebo group of the prospective BEAUTIFUL [morBidity-mortality EvAlUaTion of the If 
inhibitor ivabradine in patients with coronary disease and left-ventricULar dysfunction] 
trial and in a retrospective assessment of the Treating to New Targets [TNT] study (Fox et 
al., 2008; Ho et al., 2010). 
2.5.1 Pharmacological effects  
As heart rate increases progressively myocardial oxygen demand increases (increase in 
myocardial work) and myocardial blood flow (and with it, potential myocardial oxygen 
supply) decreases because of reduction in the duration of diastole, when coronary flow 
occurs. When a threshold value is reached at which demand is greater than supply, ischemia 
results, often causing angina. Thus, Andrews et al showed that heart rate is a predictor of 
coronary ischemia in patients with stable CAD (Andrews et al., 1993). Ivabradine selectively 
inhibits the inward sodium–potassium If current, a relatively low amplitude primary 
modifier of the rate of spontaneous depolarization of the sino-atrial (SA) node myocytes 
(discovered in 1979 by DiFrancesco, et al (Brown et al., 1979; DiFrancesco & Camm, 2004)). 
Spontaneous depolarization, itself, is a function of other calcium and potassium currents. 
Ivabradine has no other known pharmacological actions on normal cardiovascular 
physiology. Therefore, it is considered a pure heart rate slowing drug (Thollon et al., 1994). 
Resting heart rate lowering by ivabradine is comparable to that achieved with ǃ-blockers 
and is greater than that associated with CCBs (Pine et al., 1982; Tardif et al., 2005) for equal 
antianginal effect. The heart rate reduction is dose dependent (Borer et al., 2003; Thollon et 
al., 1994). Ivabradine is a selective and specific If inhibitor; it has no inotropic effect, no effect 
on relaxation (luisotropy), no impact on AV nodal conduction and no coronary 
vasoconstriction. Thus, ivabradine diminishes myocardial oxygen demand, increases 
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myocardial oxygen supply, maintains contractile force, preserves ventricular relaxation and 
allows coronary vasodilatation. The drug improves coronary perfusion and maintains 
cardiac performance better than alternative equieffective anti-anginal drug therapy.  
2.5.2 Clinical application  
The first placebo controlled trial of ivabradine for angina prevention (Borer et al., 2003) 
showed that increasing doses progressively reduced heart rate at rest and during exercise. 
With these changes, there was progressive increase in time to limiting angina and time to 
1mm ST depression on bicycle exercise; the drug also reduced the number of diary-reported 
weekly angina episodes (Borer et al., 2003). The  INITIATIVE (the INternatIonal TrIAl on the 
Treatment of angina with IVabradinE vs. atenolol) study compared ivabradine with 
atenolol ; ivabradine was  non-inferior to the beta blocker in increasing treadmill exercise 
tolerance and preventing angina at doses selected to cause heart rate reduction 
approximately equivalent to that achieved with atenolol (Tardif et al., 2005). Indeed, 
ivabradine nominally improved exercise parameters to a greater extent than atenolol, 
though these differences did not reach statistical significance. Ivabradine also reduced  
spontaneous  angina episodes  compared with baseline and was again equivalent to atenolol 
in this effect (Tardif et al., 2005). Importantly, when the specific increment in exercise 
duration was assessed as a function of heart rate reduction (“anti-anginal efficiency“) 
ivabradine was markedly and significantly more efficient than atenolol. When compared 
with amlodipine, ivabradine was non-inferior in improving exercise tolerance and 
preventing angina, and increasing time to 1 mm ST depression on exercise (Ruzyllo et al., 
2007). Though some concern initially was raised about the combination of ivabradine and 
beta blockers because of the potential for profound heart rate lowering, the  ASSOCIATE 
(Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients 
with chronic stable angina) trial of ivabradine versus placebo on a background of atenolol 
(Tardif et al., 2009) confirmed the experimental findings that ivabradine effect is « use 
dependent », i.e., the drug has its greatest rate-reducing effect at relatively high heart rates 
and has progessively less impact on heart rate as the pretherapy value decreases; more 
importantly, symptomatic bradycardia was rare with the combination, though significant 
antianginal efficacy was demonstrated with the combination compared with atenolol alone. 
When all clinical studies are considered, ivabradine has demonstrated consistent antianginal 
efficacy across all subpopulations, with reductions of 51% to 70% in the frequency of angina 
attacks (Tendera et al., 2009).  
Almost uniquely among antianginal drugs, ivabradine has been demonstrated to exert a 
benefit on natural history end-points/cardiac events. Thus, in BEAUTIFUL, Fox et al 
showed that, among patients with chronic stable CAD, LV ejection fraction <40%  and heart 
rate ≥70 bpm before therapy, heart rate reduction with ivabradine markedly and 
significantly reduced the incidence of fatal or non-fatal myocardial infarction, as well as the 
incidence of revascularization and non-MI acute coronary syndrome (Fox et al., 2008). In the 
BEAUTIFUL angina substudy (Fox et al, 2009) ivabradine not only reduced the frequency of 
angina, but it reduced the primary end-points of death, non-fatal myocardial infarction 
(both end-points similarly affected) or hospitalization for heart failure and improved quality 
of life. Among all patients in the subgroup (as well as those with pre-therapy heart rate ≥70 
bpm), all cause mortality fell 10% (and 13%), fatal or non-fatal myocardial infarction 
incidence fell 42% (and 73%); hospitalization for heart failure and coronary 
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revascularization fell 30% and 59% respectively (Fox et al., 2009). Though the BEAUTIFUL 
angina substudy was a “post-hoc” assessment that cannot be considered definitive, 
nonetheless, it strongly suggests that, for patients with angina, for whom ivabradine is 
already approved for marketing throughout Europe and other parts of the world, heart rate 
slowing with this drug has additional benefits, beyond angina prevention, in reducing major 
coronary events. In this regard, ivabradine is almost unique among all currently available 
anti-anginal anti-ischemic pharmacological agents. Though not specifically related to 
angina, the SHIFT (the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine 
Trial) study in patients with moderately severe to severe systolic heart failure  demonstrated 
the usefulness of ivabradine in reducing mortality or hospitalization for HF (Bohm et al., 
2010; Swedberg et al., 2010), irrespective of the etiology of HF. Since the study population of 
more than 6500 patients predominantly involved patients with ischemic etiology, SHIFT, 
together with BEAUTIFUL and the various antianginal trials, demonstrated the benefit of 
pure heart rate reduction by ivabradine in patients with CAD in all its manifestations. 
2.5.3 Adverse effects   
Ivabradine is safe in combination with ǃ-blockers and causes only a relatively small excess 
risk of symptomatic or dose-limiting bradycardia. The drug is well tolerated; the primary 
side effect is relatively infrequent transient and reversible “phosphenes” (flashing 
scotomata), that are sufficient to cause cessation of therapy in less than 1% of patients (Fox et 
al., 2008). This symptom is attributed to blockade of the retinal h channels, similar to the SA 
nodal f channels, by ivabradine.  
2.6 Nicorandil  
Nicorandil is a coronary and peripheral vasodilator which reduces LV preload and 
afterload. It also affects potassium channels involved in ischemic preconditioning and, thus, 
is suggested to have cardioprotective effects. The drug has been used in Europe for angina 
relief in patients with angina already receiving “conventional’ antianginal drugs. 
2.6.1 Pharmacological effects   
Nicorandil is structurally a nicotinamide ester derivative. It enhances potassium ion 
conductance by opening adenosine triphosphate (ATP)-sensitive potassium channels, in 
turn activating the enzyme guanylate cyclase. Nicorandil also has a nitrate moiety and 
promotes expression of endothelial NO synthase, thus sharing nitrate smooth muscle 
relaxing properties. Consequently, the drug enhances dilatation of arterial, venous and 
epicardial coronary arteries, resulting in reduced preload, afterload and myocardial oxygen 
demand while possibly increasing myocardial oxygen supply (Jahangir et al., 2001). 
Nicorandil may be associated with improved myocardial function during ischemia-
reperfusion, cardioprotective action during ischemia, shortened action potential duration, 
and prevention of intracellular calcium toxicity (Jahangir & Terzic, 2005; Jahangir et al., 
2001; John et al., 2003; Zingman et al., 2007). 
2.6.2 Clinical application  
Nicorandil has antianginal efficacy similar to that of ǃ-blockers, nitrates and calcium 
channels blockers. In the Impact Of Nicorandil in Angina (IONA) randomized trial, 
nicorandil 20mg twice daily showed a 17% relative risk reduction (Hazard ratio of 0.83, 
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P=0.014) in hospitalization for chest pain, MI, and cardiac death when added to standard 
antianginal therapy (Ford, 2002). However, the result was driven by effects of nicorandil on 
“hospital admission for cardiac chest pain”, and the risk reduction for cardiac death or non-
fatal MI during 1.6 years of treatment was non significant. Thus the value of the treatment 
has been disputed (Fox et al., 2006). Several small randomized trials have shown that 
Nicorandil prolongs the time to onset of ST-segment depression and exercise tolerance 
during treadmill exercise testing in patients with stable angina (Di Somma et al., 1993; 
Meeter et al., 1992; Raftery et al., 1993). Markham et al also have shown that nicorandil 
prolongs time to the onset of angina, time to 1 mm ST depression, improves exercise 
duration and reverses ischemia-related impairment in regional wall motion during exercise 
(Markham et al., 2000). In a multicenter, randomized trial (197 patients) comparing it to 
isosorbide mononitrate, nicorandil was found to be both safe and effective in preventing 
angina (Doring, 1992). A dose of 10–40 mg twice daily controls symptoms in 70%–80% of 
patients with chronic stable angina; the effect of a single administration is maintained for 
about 12 hours (Meeter et al., 1992).  
2.6.3 Adverse effects  
In the IONA trial, the drop out-rates were about 10%, mainly due to headache in the 
nicorandil group. Nicorandil is not yet approved for use in the United States, but is widely 
available for angina therapy in Europe and other countries. 
2.7 Fasudil 
Fasudil is a Rho-kinase inhibitor and a vasodilator. Rho–kinase has been identified as one of 
the effectors of the small GTP-binding protein, Rho. The Rho/Rho-kinase pathway plays an 
important role in various cellular functions including vascular smooth muscle cell 
contraction, actin cytoskeleton integrity and gene expression. As a Rho-kinase inhibitor, 
fasudil has been utilized in cerebral vasospasm, pulmonary hypertension and, recently, in 
angina. 
2.7.1 Pharmacological effects  
The Rho molecules are small GTP-binding proteins that mediate intracellular signaling by 
activation of G-protein-coupled receptors and growth factor receptors. The Rho/Rho-kinase 
signaling pathway is known to be involved in the pathogenesis of coronary artery spasm 
(Shimokawa & Takeshita, 2005). Rho molecules are  known to modulate Ca2+-sensitization 
of vascular smooth muscle cells and may act by inhibiting myosin phosphatase activity 
(Fukata et al., 2001). As a Rho-kinase inhibitor, fasudil is a vasodilator. 
2.7.2 Clinical application  
Fasudil can increase coronary artery diameter to an extent greater than that achievable with 
nitroglycerin in patients with documented vasospasm (Otsuka et al., 2008). Vasospastic 
angina precipitated by acetylcholine can be prevented by intracoronary infusion of fasudil 
(Mohri et al., 2003). When used as monotherapy, fasudil doses ranging from 5 mg three 
times daily to 40 mg three times daily have increased maximum exercise time and time to 
the onset of ST segment depression compared with baseline. Fasudil is well tolerated, with 
minimal effects on blood pressure and heart rate at rest or during exercise (Shimokawa et 
al., 2002). In a double blind, placebo controlled randomized clinical trial of 84 patients with 
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chronic stable angina, both placebo and fasudil increased exercise time on treadmill testing 
compared to baseline, but the difference between active drug and placebo was not 
statistically significant, though time to onset of ischemic ST segment depression during 
exercise was significantly prolonged compared to placebo (Vicari et al., 2005). Fasudil is not 
yet approved for use in United States. An intravenous formulation is approved in Japan to 
prevent cerebral vasospasm after subarachnoid hemorrhage. 
2.7.3 Adverse effects  
Vicari et al reported adverse effects in 41 patients and compared them to those reported 
with placebo. Overall incidence of adverse effects were similar in the 2 groups. The common 
organ systems reported to be involved were skin, subcutaneous tissue and the vascular 
system. Common disorders reported (incidence <20%) were allergic dermatitis, bruising, 
diaphoresis, facial erythema, facial flushing, hypotension or hypertension and a Raynaud-
like phenomenon. The majority of adverse events were classified as mild to moderate. No 
deaths were reported (Vicari et al., 2005). 
2.8 Trimetazidine 
Trimetazidine (1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride) is a prototype of a 
group of antianginal agents thought to act by affecting myocardial metabolism directly. 
2.8.1 Pharmacological effects  
As for most if not all antianginal drugs, the mechanism of action of trimetazidine is not fully 
clear. The proposed mechanism is direct enhancement of myocardial energy metabolism, 
resulting in cytoprotective effects (Harpey, 1989; Kay et al., 1995). Fantini et al showed that 
in isolated rat heart mitochondria, trimetazidine has an inhibitory effect on palmitoyl-
carnitine oxidation, with no significant effect on pyruvate oxidation (Fantini et al., 1994). 
This suggests that trimetazidine inhibits fatty acid oxidation in the heart. It has been shown 
that high fatty acid oxidation rates are detrimental in the setting of ischemia because of 
inhibition of the more energy efficient glucose oxidation, resulting in exacerbation of 
ischemic injury and a decrease in cardiac efficiency during reperfusion. Kantor et al 
demonstrated that trimetazidine suppresses fatty acid oxidation secondary to inhibition of 
long-chain 3-ketoacyl CoA thiolase, resulting in an increase in glucose oxidation. As a result, 
switching energy substrate preference from fatty acid oxidation to glucose oxidation may 
explain the antianginal properties of trimetazidine (Kantor et al., 2000). Unlike several other 
antianginals, trimetazidine has no effect on vascular smooth muscle and thus has been 
termed a “cellular anti-ischemic agent”. 
2.8.2 Clinical application  
The European Collaborative Working Group has demonstrated that trimetazidine is 
equivalent to propranolol in its antianginal efficiency, but is devoid of measurable 
hemodynamic effects (Detry et al., 1994). Similar results were reported in comparison with 
nifedipine (Dalla-Volta et al., 1990). Additive antianginal effects were observed when 
trimetazidine was combined with diltiazem (Levy, 1995; Manchanda & Krishnaswami, 
1997), while the benefits of combination with metoprolol were demonstrated in the 
TRIMPOL II (Szwed et al., 2001) trial. 
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2.8.3 Adverse effects  
Trimetazidine is relatively safe and is very well tolerated; there are few known drug 
interactions. Because of its safety profile, compliance has been quite good. In one 
uncontrolled trial, 2.4% of patients had adverse events during an 8-week treatment period. 
Nausea was the most frequent adverse event (0.4%) (Makolkin, 2003).  
3. Non-pharmacological therapy 
Despite maximized pharmacological therapy and life style modification, many patients with 
CAD continue to suffer from angina, including so-called “refractory angina”, which is 
defined as Canadian Cardiovascular Society (CCS) class III or IV angina with marked 
limitation during ordinary physical activity or inability to perform ordinary physical 
activity without discomfort (Gowda et al., 2005). Patients with refractory angina typically 
experience poor general health status, psychological distress, impaired role functioning, 
activity restriction, and inability to manage their living situation (Brorsson et al., 2002; 
Erixson, 1997; McGillion et al., 2007). Refractory angina is debilitating and its treatment is 
challenging. In the past several decades, a number of nonpharmacological treatments have 
been developed to help resolve this problem. These therapies will be outlined in this section. 
3.1 Mechanical therapy 
3.1.2 Revascularization 
Coronary angiography and possible revascularization should be considered in patients with 
refractory angina. Revascularization includes percutaneous coronary interventions (PCI) 
and coronary artery bypass graft surgery.  
3.1.2.1 Percutaneous coronary intervention 
PCI, initially involving balloon angioplasty and later generally comprising balloon 
angioplasty plus stent placement to support and maintain the new channel, was developed  
for the relief of angina in patients refractory to medication. This remains one of the few data-
supported applications of the technique. 
3.1.2.1.1 Evidence 
A comparison of balloon angioplasty with  pharmacological therapy in  treating patients 
with single vessel CAD (ACME) showed that angioplasty resulted in a greater proportion 
of patients free of angina at 6 months and greater improvement in treadmill exercise 
duration than did pharmacological therapy (Parisi et al., 1992). This study predated the 
routine use of stents and manifested a high rate (20%) of PCI failure but nonetheless 
supported the superiority of mechanical angioplasty to drug therapy alone for angina 
prevention. The multicenter Randomized Intervention Treatment of Angina (RITA) 2 trial 
was one of the largest trials prospectively assessing the impact of balloon angioplasty vs 
medical therapy on angina. Angina was of relatively mild severity (CCS 0-2) in 80 % of 
patients (Chamberlain, 1997). Angina frequency, exercise time and quality of life all 
improved in both groups. However, the subgroup of patients with CCS≥2 derived 
significantly greater symptom-relieving benefit from PCI than from pharmacological 
therapy during a 1 year follow-up interval. By 3 years, this advantage was lost, though 
interpretation of this finding is confounded by a relatively high (23%) crossover rate of 
medically treated patients to PCI. The Atorvastatin versus Revascularization Treatment 
(AVERT) trial assessed patients with angina CCS class 0-2. In this study, half the PCI 
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group received stents as well as balloon angioplasty (Pitt et al., 1999). Patients in the PCI 
group evidenced greater improvement than those receiving pharmacological therapy.  
Bucher et al conducted a systematic review of 6 trials from 1979 through1998, including a 
total of 1904 patients with stable single vessel CAD and normal LV function (4). Balloon 
angioplasty was associated with a significant improvement in angina compared with 
pharmacological therapy alone. There was no difference of mortality or myocardial 
infarction between PCI and drug therapy (Bucher et al., 2000). Recently, 2 trials, MASS 
(Medicine, Angioplasty or Surgery Study) II (Hueb et al., 2004) and COURAGE (Clinical 
Outcomes utilizing Revascularization and Aggressive Drug Therapy) (Boden et al., 2007) 
compared PCI versus pharmacological therapy in stable CAD. MASS-II  included 611 
patients; after 1 year of follow up, 79% of patients in PCI group, 88% of patients in 
surgery group and 46% in medical therapy group were free of angina, though no 
difference was found in mortality rates among the groups. COURAGE compared initial 
PCI with “optimal medical management”. At baseline, 43% of patients either did not have 
symptoms or had Class 1 angina. After 5 years follow up, 74% of patients in the PCI group 
and 72% patients in the medical therapy group were free of angina. By this time, one-third 
of patients had crossed over from medical therapy to PCI group. No evidence of benefit 
was found in terms of mortality or major morbidity when the groups were analyzed 
according to intention to treat. 
3.1.2.1.2 Conclusion  
The decision to perform PCI for symptom relief in patients with angina remains complex 
and needs to be individualized based on analysis of  goals and risks. The relevant trials 
performed to date have important limitations for extrapolation to current decisions  
including the possible impact of recent improvements in PCI techniques, changes in 
pharmacology and alterations in the populations at risk, in part because of drug therapy 
that can modify atherosclerosis. Most trials show that PCI results in greater symptom relief 
and better exercise tolerance than drug therapy but suggest that this advantage is of 
relatively limited duration, requiring adjunctive or additional therapy to maintain anti-
anginal benefits. However, for patients with angina refractory to pharmacological therapy, 
current evidence clearly supports PCI as an appropriate therapy for symptom improvement. 
Nonetheless, because of the rapidly changing landscape of therapy noted above, the 
appropriate approach to achieve optimal symptom prevention is a moving target, and more 
studies would be useful.  
3.1.2.2 Coronary artery bypass grafting (CABG) surgery 
CABG is an important therapeutic modality for millions of patients with CAD. Surgery has 
evolved over the more than 4 decades since its introduction, both in terms of duration of 
benefit (open arteries) and in reduction of peri-operative complications. 
3.1.2.2.1 Evidence 
Early trials included the European Coronary Surgery Study (ECSS) (Varnauskas, 1988), 
Veterans Cooperative Study (Detre, 1984) and Coronary Artery Surgery Study (CASS) 
(Killip, 1983). These studies were designed to assess the benefits of CABG for survival and 
prevention of major morbidity, but provided information about angina prevention, as well. 
In each of these studies, CABG was compared with medical therapy in patients with stable 
CAD and angina. Yusuf et al conducted a meta-analysis of earlier surgery trials which 
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included a total of 2649 patients in which outcomes were evaluated at 5 and 10 years (Yusuf 
et al., 1994). CABG improved survival compared with pharmacological therapy. 
Importantly, though, CABG also produced greater freedom from symptoms and less use 
of antianginal medications than pharmacological therapy during a 5 year follow-up. Not 
surprisingly, benefits were greatest among those with the most severe disease at 
randomization, those with left main or multivessel disease and those with one or two 
vessel disease involving the proximal left anterior descending artery. Survival benefits 
were greater among patients with at least moderately subnormal LV ejection fraction than 
among those with normal LV performance. Bypass Angioplasty Revascularization 
Investment (BARI) trial was the largest (1829 patients) randomized study comparing 
balloon angioplasty versus CABG in symptomatic multivessel CAD (Alderman, 1996). 
After 10 years of follow up, angina rates in the two groups were similar. There were 
higher subsequent revascularization rates in balloon angioplasty group than in those who 
were randomized to CABG. Also, as noted above, MASS-II showed that 88% of patients in 
surgery group, 79% of patients in PCI group and 46% in medical therapy group were free 
of angina at pre-specified follow-up (Hueb et al., 2004). Bravata et al did a meta-analysis 
of 23 trials which included a total of 9963 patients, indicating that angina was relieved at 5 
years in 79% of PCI patients and 84% of CABG patients (Bravata et al., 2007). Data also 
indicate that approximately 80-90% patients who are symptomatic on medical therapy 
become symptom free following CABG. This benefit has been shown to extend even to 
low-risk patients in whom mortality benefit with surgery has not been shown (Yusuf et 
al., 1994).  
3.1.2.2.2 Conclusion  
Both CABG and PCI are effective in relieving angina but CABG achieves this benefit with 
less need for  repeat procedures than does PCI. In addition, though not specifically relevant 
to angina relief, several subsets of patients with chronic stable CAD can anticipate survival 
benefit from CABG; no parallel data are available for PCI. However, many of the relevant 
data were obtained with techniques and devices that have been superseded in this rapidly 
developing area. Thus, more data with the most up-to date techniques would be useful, on a 
background of the most modern pharmacological therapy to beneficially alter CAD 
progression. Nonetheless, as suggested by data from matched cohorts from the New York 
State coronary surgery database (Hannan et al., 2005), even as PCI techniques develop, 
CABG remains superior in terms of survival but the effects of newer approaches on angina 
remain to be defined. 
3.1.3 Enhanced External Counterpulsation  
Enhanced External Counterpulsation (EECP) is a non-invasive treatment that has been 
studied and employed with variable success for more than 30 years (Amin et al., 2010). 
EECP is carried out by placing compressible cuffs around the calves and lower and upper 
thighs, inflating them sequentially during diastole and deflating them simultaneously at the 
onset of systole. Throughout this process, the patient is connected to an electrocardiogram 
(ECG) and a finger plethysmograph. The R wave of the ECG is used to gate inflation and 
deflation. Treatment typically involves 35 sessions, each lasting 1 hour, undertaken over a 7-
week interval (Sinvhal et al., 2003). EECP is believed to improve coronary perfusion 
pressure through diastolic augmentation while decreasing cardiac workload by reducing 
aortic impedance during systole.  
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3.1.3.1 Evidence  
EECP is generally considered acceptably safe and is without specific contraindications. The 
few adverse effects associated with EECP generally are related to the physical characteristics 
of the equipment and its application, e.g., leg and back pain, abrasion of skin, bruising, 
blistering, edema and paresthesia (Arora et al., 1999). The effectiveness of EECP for 
refractory angina has been investigated in several studies over the last two decades. In the 
only published randomized clinical trial (Arora et al., 1999), the Multicenter Study of 
Enhanced External Counterpulsation (MUST-EECP), which involved 139 patients with 
angina and documented CAD, patients were randomised to either 35 h of active 
counterpulsation (300 mm Hg maximal cuff pressure) or inactive counterpulsation (75 mm 
Hg maximal cuff pressure) over a 4–7 week-period. Exercise duration increased in both 
groups to a similar degree (p > 0.3) and nitroglycerin use did not differ between groups 
(P>0.7). However, time to ≥1-mm ST segment depression (exercise-induced ischemia) 
increased significantly from baseline in active counterpulsation compared with inactive 
counterpulsation (p = 0.01). More active counterpulsation patients saw a decrease and fewer 
experienced an increase in angina episodes as compared with inactive counterpulsation 
patients (p < 0.05). The investigators concluded that EECP reduced angina and extended 
time to exercise-induced ischemia in patients with symptomatic CAD. Treatment was 
relatively well tolerated and was free of limiting side effects in most patients. The limitations 
of this trial include fairly stringent patient selection criteria precluding simple extrapolation 
of the data, the preponderance of patients with only Class I or II symptoms, and the lack of 
data about natural history outcomes. Also, there were more withdrawals due to adverse 
effects in active EECP group than in the control group. 
To further assess EECP effects on both exercise tolerance and cardiac function, Urano et al 
(Urano et al., 2001) examined 12 stable patients with CAD and evidence of exercise-induced 
myocardial ischemia despite conventional medical or surgical therapies. These investigators 
found that, compared with baseline values, EECP improved all exercise test parameters, 
reduced exercise-induced reversible perfusion defects by thallium scintigraphy, and 
improved diastolic filling and LV end-diastolic pressure. These hemodynamic 
improvements were associated with decreased plasma brain natriuretic peptide levels. The 
investigators concluded that EECP definitely was effective in patients with CAD. 
To clarify the mechanism underlying EECP benefits,  Shechter et al (Shechter et al., 2003)  
investigated the influence of short-term EECP on vascular endothelial function in patients 
with CAD. They used high-resolution ultrasound to assesse endothelium-dependent 
brachial artery flow-mediated dilation (FMD) and endothelium-independent nitroglycerin-
mediated vasodilation before and after EECP therapy. EECP resulted in significant 
improvement in post-intervention FMD but no significant effect on nitroglycerin-induced 
vasodilation. EECP significantly reduced angina as assessed by mean daily sublingual 
nitrate consumption and mean CCS angina class. The investigators concluded that EECP 
improved vascular endothelial function and angina in patients with CAD and refractory 
angina pectoris, suggesting a causal relation.  
Few studies have evaluated the long-term effects of EECP. Loh et al (Loh et al., 2008) used 
the International EECP Patient Registry (IEPR-1) that enrolled consecutive patients treated 
with EECP in more than 100 centers; follow-up duration was 3 years. These investigators 
found that immediately post-EECP, the proportion of patients with severe angina (CCS 
III/IV) was reduced from 89% to 25% (p<0.001). The benefit was sustained in 74% during 
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follow-up. This is the longest follow-up from IEPR-1 to date and tends to confirm the safety 
and immediate benefits of EECP as well as suggesting that sustained symptomatic and 
quality of life benefit can be achieved in most patients for up to 3 years. However, this 
observational study lacked a control group, weakening the conclusions. Further, the results 
are impaired by patient selection and survival bias. Other non- randomized studies 
(Barsheshet et al., 2008; Holubkov et al., 2002; Shechter et al., 2003; Urano et al., 2001) have 
been difficult to interpret. All assessments need to be treated with considerable caution due 
to selection bias and absence of blinding (McKenna et al., 2009).  
3.1.3.2 Conclusion  
With its development, it was hoped that EECP would be a viable adjunct for patients with 
CAD patients and angina inadequately responsive to medication and revascularization. To 
date, results from well-designed clinical trials are relatively few. However, these data 
provide a suggestion of no more than limited clinical effectiveness. Issues of adverse effects 
and cost-effectiveness have limited application of EECP therapy. Finally, evaluation in a 
truly refractory population with predominantly Class III/IV patients has not been 
undertaken. The ACC/AHA 2002 guideline update for the management of patients with 
chronic stable angina assigns EECP therapy a level of evidence of Class IIB (the usefulness/ 
efficacy is less well established by evidence/opinion). This suggests there may be some 
benefit, but additional clinical trial data are needed before EECP can be recommended 
definitively (Gibbons et al., 2003). EECP was not mentioned in the 2007 Chronic Angina 
Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients with 
Chronic Stable Angina (Fraker et al., 2007). Thus, additional data from randomized 
controlled trials are needed with regards to exercise tolerance, angina frequency and 
nitroglycerin use, ischemia reduction and, if possible, long term benefit on quality of life, as 
well as mortality or major morbid cardiovascular events.  
3.1.4 Carotid Sinus Nerve Stimulation 
Fifty years ago, carotid sinus nerve stimulation (CSNS) to slow heart rate and, to a lesser 
extent, to lower blood pressure was conceived (Lown & Levine, 1961) as an alternative 
treatment for refractory angina. Stimulation of the carotid sinus nerves reflexly reduces the 
frequency of sympathetic efferent impulses which, in turn, results in reduction in arterial 
pressure, myocardial contractility, and heart rate; as a consequence, myocardial oxygen 
demand is diminished and angina is relieved. Small, non-randomized studies demonstrated 
that CSNS relieved angina and allowed patients to perform more exercise without 
developing angina (Braunwald et al., 1967; Epstein et al., 1969; Rotem, 1974). However, due 
to the need for invasive implantation of the stimulator using the somewhat crude methods 
of the time, CSNS never was broadly applied. Nonetheless, it proved the principle that 
angina relief could be achieved directly by altering certain hemodynamic variables.  
3.1.5 Spinal Cord Stimulation 
Spinal cord stimulation (SCS), also called dorsal column stimulation or neurostimulation, is 
a neuromodulation therapy to alleviate pain by electrically activating pain-inhibiting 
neuronal circuits in the dorsal horn and inducing paresthesia that masks the original pain 
sensations. Local anesthesia is used during SCS implantation, via an incision at the level of 
thoracic vertebrae 6-8, an electrode is inserted into the epidural space and guided via X-ray 
monitoring up to the level of the thoracic 1-2 vertebrae. Its location is adjusted until the 
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patient experiences paresthesiae within the area of the anginal pain. An extension wire is 
then tunneled subcutaneously via an incision to the left flank, where it is connected to a 
subcutaneous pulse-generator below the left costal arch. The stimulation intensity is then 
fine-tuned post-operatively. The patient can regulate the strength of the actual stimulation 
using a remote control (Borjesson et al., 2008). SCS has been successfully reported to relieve 
pain in a number of chronic conditions including neuropathic pain and peripheral vascular 
disease (Kemler et al., 2000; Kumar et al., 2007; Lee & Pilitsis, 2006). Since the late 1980s, SCS 
has been used to treat patients with chronic refractory angina who are not responsive to  
conventional medical therapy and revascularization (Murphy & Giles, 1987). Although the 
underlying mechanism is not fully elucidated, it has been proposed that SCS exerts 
beneficial effects by decreasing pain and sympathetic tone, yielding reductions in 
myocardial oxygen consumption and improved myocardial microcirculatory blood flow 
(Latif et al., 2001).  
3.1.5.1 Evidence  
Published evidence supports SCS as effective and acceptably safe for patients with 
refractory angina who are unresponsive to medical and surgical intervention (Bondesson et 
al., 2008; de Vries et al., 2007; Diedrichs et al., 2005; Dyer et al., 2008; Eddicks et al., 2007; 
Lapenna et al., 2006; McNab et al., 2006). Recently, a meta-analysis of 7 randomized 
controlled trials involving 270 patients (Taylor et al., 2009) found benefits similar to those of 
CABG and percutaneous myocardial laser revascularization (PMR). Compared to the 
control, there was some evidence of improvement in all outcomes following SCS 
implantation with significant gains observed in pooled exercise capacity and health related 
quality of life. However, the trials were small and varied considerably in quality. The 
healthcare costs of SCS appeared to be lower than CABG at 2-years follow up. One 
particular challenge of SCS evaluation is the difficulty in patient blinding, as the therapy 
produces paresthesia in the area of the pain if SCS is effective. In addition, the implantation 
procedure might produce a placebo effect, but sham operations are ethically difficult to 
justify (Van Zundert, 2007). Further high quality trials and cost effectiveness evidence is 
needed before SCS can be accepted as a routine treatment for refractory angina. 
3.1.5.2 Conclusion  
SCS has been used for treatment of refractory angina in Europe for 20 years. In the European 
Society of Cardiology guidelines on management of angina (Fox et al., 2006), SCS is accepted 
as a “well established method” for the management of refractory angina. Patients experience 
a favorable analgesic effect and positive effects on symptoms from SCS, though long-term 
effects are unknown. The ACC/AHA guidelines for the management of patients with 
chronic stable angina (Fraker et al., 2007; Gibbons et al., 2003) provided a class II b 
recommendation, suggesting that SCS should only be used in patients who cannot be 
managed adequately by medical therapy and who are not candidates for revascularization. 
3.1.6 Transmyocardial revascularization 
Transmyocardial revascularization (TMR) applies high-energy laser beams to create non-
transmural endomyocardial channels. These channels can be generated surgically, using an 
epicardial approach, or percutaneously (PMR), via catheter, an endocardial approach. The 
basis for angina prevention with TMR is unclear. The initial hypothesis was that the 
channels provided oxygenated blood from the LV to directly perfuse the myocardium; 
support for this mechanism is not compelling; more recently, it has been proposed that 
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clinical improvement may be secondary to angiogenesis, placebo effect, or myocardial 
denervation (Huikeshoven et al., 2002). TMR also has been combined with administration of 
angiogenic growth factors and/or angiogenic gene vectors introduced via the channels to 
stimulate angiogenesis (see Biological Therapy, below). 
3.1.6.1 Evidence  
Since its initial application in association with CABG in 1983, surgical TMR has been 
considered an alternative for patients with refractory angina who were not amenable to 
conventional revascularization (Smith et al., 1995). However, though several preliminary 
studies demonstrated a decrease in angina severity in most patients (Cooley et al., 1996; 
Horvath et al., 1996), subsequent randomized controlled trials (RCT) have reported 
contradictory results (Aaberge et al., 2000; Burkhoff et al., 1999; Campbell et al., 2001; Jones 
et al., 1999; March, 1999; van der Sloot et al., 2004). Briones et al (Briones et al., 2009) 
conducted a Cochrane systematic review to assess the efficacy and safety of TMR versus 
optimized drug therapy in alleviating angina and improving survival and heart function. 
The 7 RCTs included in the review involved 1137 patients of whom 559 were randomized to 
TMR. Overall, 43.8% of patients in the treatment group decreased two angina classes, 
compared to 14.8% in the control group (95% confidence interval 3.43 to 6.25). Mortality 
analyzed on an intention-to-treat basis was similar in both groups at 30 days (4.0% in the 
TMR group vs. 3.5% in the control group) and at one year (12.2% in the TMR group vs. 
11.9% in the control group). However, the per protocol 30-day mortality was 6.8% in the 
TMR group compared to 0.8% in the control group (OR 3.76 [95% CI, 1.63 to 8.66]). The 
authors concluded that evidence is insufficient to support the presumption that clinical 
benefits of TMR outweigh the potential risks. Importantly, the observed improvement in 
angina was not measured using blinded methods and is therefore subject to significant 
potential bias, and there was no difference in survival.  
PMR is less invasive than TMR, utilizing a fiberoptic catheter inserted through a femoral 
artery under conscious sedation to carry the laser energy to the endocardial surface. Laser 
firing is synchronized during systole to create a series of nontransmural channels in targeted 
regions (Oesterle et al., 1998). Recently McGillion et al (McGillion et al., 2010) conducted a 
meta-analysis to assess the effectiveness of PMR versus optimized drug therapy for 
reducing angina and improving health-related quality of life (HRQL), and exercise 
performance. Seven RCT trials, involving 1,213 participants, were included. At 12-month 
follow-up, the PMR group had more than 2 CCS class symptom reductions as well as 
improvements in HRQL, disease perception and physical limitations. However, PMR had 
no significant impact on all-cause mortality. In the secondary analyses, in which the data 
were from a single trial that employed a higher-dose laser group, the result showed no 
significant overall impact of PMR across outcomes.  
3.1.6.2 Conclusion  
When applied in carefully selected patients with refractory angina, TMR can provide 
durable reduction in self-reported angina and improvement in quality of life compared to 
drug treatment alone. However, evidence of improvement in exercise tolerance, the 
“objectification” of angina, is less strong, and impact on survival has not been 
demonstrated. For PMR, evidence is insufficient to demonstrate efficacy for angina 
prevention (and, therefore, of benefit to risk relation). Long-term outcomes of PMR are not 
clear. PMR devices have not been approved by the FDA due to lack of adequate evidence of 
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efficacy in their use. ACC/AHA guidelines (Eagle et al., 2004; Gibbons et al., 2003) 
recommend TMR as a Class IIa procedure, stating that TMR alone or in combination with 
CABG is reasonable in patients with angina refractory to medical therapy who are not 
candidates for PCI or CABG but does not recommend PMR, noting that it should still be 
considered experimental. 
3.2 Biological therapy 
3.2.1 Angiogenic gene therapy 
Angiogenesis is the biological process involving formation of new blood vessels from pre-
existing vessels under physiological or pathological conditions. In patients with chronic 
CAD, angiogenesis in response to repeated myocardial ischemia can provide collateral 
blood flow to muscle distal to sites of coronary stenoses. Theoretically, stimulation of 
angiogenesis presents an attractive approach for the treatment of CAD. Attempts at 
therapeutic angiogenesis have employed molecules (growth factors) shown experimentally 
to improve jeopardized blood supply, thereby relieving myocardial ischemia, improving 
regional and global LV performance, lessening angina, and improving clinical outcomes 
(Simons & Ware, 2003). A number of growth factors have been demonstrated to stimulate 
blood vessel growth in humans and are the focus of recent angiogenic gene therapy studies. 
These include several fibroblast growth factors (FGFs), vascular endothelial growth factors 
(VEGFs) and granulocyte/macrophage colony stimulating factor (GM-CSF) (Zachary & 
Morgan, 2011). 
3.2.1.1 Evidence  
How to effectively and safely deliver growth factors to the target tissue remains a major 
problem in therapeutic angiogenesis trials. The accepted consensus is that effective 
angiogenic intervention will require the presence of the therapeutic agent at the desired site 
of action for as long as four to six weeks. In early experience, delivery of growth factors was 
achieved either by systemic infusion or intracoronary infusion, but results were 
disappointing, perhaps because of short residence time of the infused proteins in target 
tissues. Repeated administration or the use of sustained release polymers may prove more 
effective, but remains to be tested. Introduction of angiogenic genes into the myocardium 
offers a theoretical alternative approach to delivery that might obviate the need for repeated 
administrations of short-lived proteins, and avoid the potential risks of short-term systemic 
exposure to relatively high concentrations of proteins (Simons et al., 2000). Introduction of 
angiogenic genes with both plasmid and adenoviral vectors has been associated with 
improvements in heart function and perfusion in different animal models of myocardial 
ischaemia (Hammond & McKirnan, 2001). Several clinical gene therapy trials of angiogenic 
growth factors have been conducted using either plasmid or adenoviral vectors. Effects of 
intramyocardially delivered plasmid VEGF were assessed in two randomised, double-
blinded, placebo-controlled trials, EUROINJECT-ONE (Kastrup et al., 2005) and 
NORTHERN (Stewart et al., 2009)  involving, respectively, 80 and 93 patients with severe 
stable ischemic heart disease (CCS III/IV). Neither trial demonstrated alteration in the 
primary end point, change in myocardial perfusion, by therapy, despite the use of a high 
plasmid dose (2 mg) in the NORTHERN study. There was a trend toward improvement in 
exercise treadmill time and angina reduction, but again no significant differences were 
observed. Another RCT, REVASC (Stewart et al., 2006) employed an adenoviral vector 
(AdVEGF121) delivered into the myocardium at surgery in 67 patients with refractory 
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angina. In this study, a statistically significant increase in the primary end point, time to 1 
mm ST-segment depression on treadmill exercise, was observed at 26 weeks in the active 
treatment group. Another RCT, KAT (Hedman et al., 2003), compared AdVEGF165 with 
either plasmid VEGF or placebo for effect on myocardial perfusion in 103 patients. In this 
trial, the vectors were administered by intracoronary injection at angioplasty. There was no 
significant difference in the rates of restenosis between treatment groups at 6 months, but 
myocardial perfusion improved in the AdVEGF165 group compared with plasmid VEGF. In 
an 8-year follow-up study of the KAT trial, the incidence of major adverse cardiovascular 
events, cancer or diabetes did not differ between the treatment groups (Hedman et al., 2009). 
A series of AGENT trials investigated the safety and efficacy of intracoronary injections of 
an adenoviral-encoded FGF-4 gene. The AGENT-1 trial (Grines et al., 2002) enrolled 79 
patients and found a trend toward improved exercise time at four weeks in treatment group 
compared to the placebo group; when only patients with baseline exercise time ≤10 minutes 
were considered, exercise time increased significantly. The subsequent AGENT-2 trial of 52 
patients with AdFGF-4 found a nonsignificant reduction in the size of the ischemic defect on 
perfusion imaging between treatment and placebo (Kapur & Rade, 2008). However, two 
large double-blind phase III trials of Ad-FGF4 (AGENT-3 and AGENT-4) were negative for 
their primary end point although a post-hoc analysis suggested a benefit in a certain 
population of middle aged women (Henry et al., 2007).  
3.2.1.2 Conclusion  
Though therapeutic angiogenesis theoretically is an attractive option for improving the 
quality of life in chronic ischemic heart disease, no large clinical trial yet has shown 
substantial clinical benefit. However, efforts are ongoing to improve delivery and 
expression and biological efficacy of the angiogenic genes (Zachary & Morgan, 2011).  
3.2.2 Stem cell therapy 
Hematopoietic stem cells are bone marrow-derived cells capable of differentiating into a 
variety of cell types. Such cells may be obtained directly from the bone marrow or, using 
apheresis techniques, from peripheral blood, usually after stimulation with granulocyte-
colony stimulating factor (G-CSF). Cardiac stem cell therapy has been evaluated clinically 
during the past 10 years. Many clinical trials have been conducted on treatment for heart 
failure (Menasche et al., 2008; Stamm et al., 2007) and acute MI (Martin-Rendon et al., 2008) 
but the study of stem cell therapy for refractory angina is in early stages of development. 
The mechanisms of potential benefit remain uncertain. The initial hypothesis of 
transdifferentiation into cardiomyocytes no longer is generally accepted (Murry et al., 2004). 
The currently favored hypothesis is that increased angiogenesis is stimulated by angiogenic 
growth factors released by bone marrow cells, particularly by the CD34+ fraction 
(Menasche, 2011).  
3.2.2.1 Evidence  
Losordo et al (Losordo et al., 2007) showed the efficacy of intramyocardial transplantation of 
autologous G-CSF-mobilized peripheral blood CD34+ stem cells for prevention of angina. 
Twenty-four patients with CCS class III or IV angina who were undergoing optimized 
medical treatment and who were not candidates for mechanical revascularization were 
enrolled in a double-blind, randomized (3:1), placebo-controlled dose-escalating study. 
CD34+ progenitors were collected following GCSF-induced cell mobilization and apheresis. 
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Electromechanical mapping was performed to identify ischemic but viable regions of 
myocardium for injection of cells (versus saline). The intramyocardial injection of cells or 
saline did not result in cardiac enzyme elevation, perforation, or pericardial effusion. 
Neither ventricular tachycardia nor ventricular fibrillation occurred during the 
administration of G-CSF or intramyocardial injections. Efficacy parameters including angina 
frequency, nitroglycerin usage, exercise time, and CCS class showed trends that favored 
CD34+ cell–treated patients versus placebo-treated controls. A phase II b study in a larger 
population is currently under way. 
A recent RCT of intracoronary infusion with autologous bone marrow CD34+ stem cells 
involved 112 patients with intractable angina (Wang et al., 2010). No myocardial infarction 
or other major adverse event was observed during the procedure. Investigators found 
significantly greater reduction in angina frequency by diary at 3 and 6 months after active 
treatment than after control. Other efficacy parameters, such as nitroglycerin use, exercise 
time and the CCS class, also were improved by active treatment versus control, as was 
myocardial perfusion imaging assessment of ischemia. 
3.2.2.2 Conclusion  
Stem cell therapy is an investigational technique that has reduced angina frequency and 
severity by several measures in small populations with refractory angina. However, 
additional studies are required to determine the magnitude, consistency and durability of 
anti-anginal benefit, as well as the long-term safety of this approach for treatment of patients 
with angina due to CAD. 
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